KS
Katherine Stueland (Chief Executive Officer) filed 12 Form 4 reports in the trailing twelve months (0 purchases, 12 sales), most often in GeneDx Holdings Corp. (WGS). The largest single filing was $3.0M of WGS (46,933 sh across 5 lots, as filed), executed Mar 26. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
12
0 buys · 12 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$10.9M
shares × price, as filed
Last traded
Sep 16
Filed Sep 18
Median ADV $82.7M across their filed names
Open performance→Volume by month
Buys $0
Sells $33.8M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
12 filings
Sector per market data · by filing · past 12 months
Most traded names
WGSRecent filings
WGSSALE
GeneDx Holdings Corp.
View filing →
$1.0M10,559 sh × $96.71
Exec Mar 17 2025
Filed Mar 17 2025 · 5:30 PM ET WGSSALE GeneDx Holdings Corp. View filing → $259K
2,731 sh × $94.73
Exec Mar 10 2025
Filed Mar 11 2025 · 5:30 PM ET WGSSALE GeneDx Holdings Corp. View filing → $130K
1,657 sh × $78.48
Exec Jan 29 2025
Filed Jan 31 2025 · 5:30 PM ET WGSSALE GeneDx Holdings Corp. View filing → $4.9M
51,420 sh across 4 lots
Exec Jan 7 2025
Filed Jan 10 2025 · 5:30 PM ET †